Statins enhance clonal growth of late outgrowth endothelial progenitors and increase myocardial capillary density in the chronically ischemic heart

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Wang, Wen ^a   Lang, Jennifer K ^b   Suzuki, Gen ^b   Canty Jr , John M ^b   Cimato, Thomas ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; ATORVASTATIN; CD31 ANTIGEN; CD45 ANTIGEN; ENDOGLIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; SIMVASTATIN; STEM CELL FACTOR RECEPTOR; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CAPILLARY DENSITY; CELL CULTURE; CELL GROWTH; CELL MOTILITY; CHRONIC DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENDOTHELIAL PROGENITOR CELL; FEMALE; HEART FAILURE; HEART MUSCLE CAPILLARY; HEART MUSCLE ISCHEMIA; ISCHEMIC HEART DISEASE; LATE OUTGROWTH ENDOTHELIAL PROGENITOR CELL; MALE; MONONUCLEAR CELL; NONHUMAN; PROTEIN PHOSPHORYLATION; SWINE; ANIMAL; CYTOLOGY; ENDOTHELIUM CELL; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; PATHOLOGY; STEM CELL; WESTERN BLOTTING;

ANIMALIA; SUIDAE;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; FLOW CYTOMETRY; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; MICROSCOPY, FLUORESCENCE; MYOCARDIAL ISCHEMIA; PRAVASTATIN; STEM CELLS; SWINE;

EID: 80052718427     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024868     Document Type: Article

References (32)

1. Gheorghiade M, Bonow RO, (1998) Chronic heart failure in the United States. Circulation 97: 282-289.
2. Suzuki G, Iyer V, Cimato T, Canty JM Jr, (2009) Pravastatin improves function in hibernating myocardium by mobilizing CD133+ and c-kit+ bone marrow progenitor cells and promoting myocytes to reenter the growth phase of the cardiac cell cycle. Circulation Research 104: 255-64.
3. Boodhwani M, Mieno S, Voisine P, Feng J, Sodha N, et al. (2006) High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine. J Thorac Cardiovasc Surg 132: 1299-1306.
4. Bearzi C, Leri A, LoMonaco F, Rota M, Gonzalez A, et al. (2009) Identification of a coronary vascular progenitor cell in the human heart. Proc Natl Acad Sci 106: 15885-90.
5. Hirschi KK, Ingram DA, Yoder MC, (2008) Assessing identity, phenotype and fate of endothelial progenitor cells. Arteriosclerosis Thrombosis and Vascular Biology 28: 1584-95.
6. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, et al. (2007) Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109: 1801-9.
7. Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, et al. (2004) Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 104: 2752-60.
8. Broxmeyer HE, Srour E, Orschell C, Ingram DA, Cooper S, et al. (2006) Cord blood stem and progenitor cells. Methods in Enzymology 419: 439-73.
9. Ingram DA, Krier TR, Mead LE, McGuire C, Prater DN, et al. (2007) Clonogenic endothelial progenitor cells are sensitive to oxidative stress. Stem Cells 25: 297-304.
10. Fallavollita JA, Perry BJ, Canty JM Jr, (1997) 18F-2-deoxyglucose deposition and regional flow in pigs with chronically dysfunctional myocardium. Evidence for transmural variations in chronic hibernating myocardium. Circulation 95: 1900-9.
11. Hatanaka T, (2000) Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 39: 397-412.
12. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, et al. (2001) HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/AKT pathway. J Clin Invest 108: 391-7.
13. Skaletz-Rorowski A, Kureishi Y, Shiojima I, Walsh K, (2004) The pro- and antiangiogenic effects of statins. Semin Vasc Med 4 (4): 395-400.
14. Skaletz-Rorowski A, Walsh K, (2003) Statin therapy and angiogenesis. Curr Opin Lipidol 14 (6): 559-603.
15. Arnaoutova I, Kleinman HK, (2010) In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. Nature Protocols 5: 628-635.
16. Kubota Y, Kleinman HK, Martin GR, Lawley TJ, (1988) Role of laminin and basement membrane in the morphologic differentiation of human endothelial structures into capillary-like structures. J Cell Biol 107: 1599-1610.
17. Urbich C, Dernbach E, Zeiher AM, Dimmeler S, (2002) Double-edged role of statins in angiogenesis signaling. Circ Res 90: 737-744.
18. Ashahara T, Murohara T, Sullivan A, Silver M, van der Zee R, et al. (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964-7.
19. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, et al. (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. New England Journal of Medicine 348: 593-600.
20. Case J, Mead LE, Bessler WK, Prater D, White HA, et al. (2007) Human CD34+AC133+VEGFR2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 35: 1109-18.
21. Timmermans F, Van Hauwermeiren F, De Smedt M, Raedt R, Plasschaert F, et al. (2007) Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol 27: 1572-9.
22. Yoder MC, (2010) Is endothelium the origin of endothelial progenitor cells? Arterioscler Thromb Vasc Biol 30: 1094-1103.
23. Oberlin E, Tavian M, Blazsek I, Peault B, (2002) Blood-forming potential of vascular endothelium in the human embryo. Development 129: 4147-4157.
24. Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G, (1998) A common precursor for hematopoietic and endothelial cells. Development 125: 725-732.
25. Ueno H, Weissman IL, (2006) Clonal analysis of mouse development reveals a polyclonal origin for yolk sac blood islands. Developmental Cell 11: 519-533.
26. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK, (2006) Primary prevention of cardiovascular diseases with statin therapy: A meta-analysis of randomized controlled trials. Arch Intern Med 166: 2307-2313.
27. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al. (2004) Intensive versus moderate lipid lowereing with statins after acute coronary syndromes. N Engl J Med 350: 1495-1504.
28. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, et al. (2005) Intensive lipid lowering with Atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425-35.
29. Weis M, Heeschen C, Glassford AJ, Cooke JP, (2002) Statins have biphasic effects on angiogenesis. Circulation 105: 739-745.
30. Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD, (2009) Molecular basis of statin-associated myopathy. Atherosclerosis 202: 18-28.
31. Mason RP, Walter MF, Day CA, Jacob RF, (2005) Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors contribute to distinct pharmacologic and pleiotrophic actions. Am J Cardiol 96: 11F-23F.
32. Dubois C, Liu X, Claus P, Marsboom G, Pokreisz P, et al. (2010) Differential effects of progenitor cell populations on left ventricular remodeling and myocardial neovascularization after myocardial infarction. J Am Coll Cardiology 55: 2232-43.